



# **11th Paris Hepatology Conference 2018**

## ***Palais des Congrès***

***Paris 15,16 January 2018***

Hepatitis C in Italy

---

Massimo Colombo, MD

Center for Translational Research in Hepatology, Humanitas Hospital, Rozzano, Italy.

EASL International Liver Foundation, Geneva, Switzerland

PHC 2018 - [www.aphc.info](http://www.aphc.info)

---

# Financial Disclosures

---

Grant and research support: BMS, Gilead Science

Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science,  
Tibotec, Vertex, Janssen Cilag, Achillion, Lundbeck, GSK,  
GenSpera, AbbVie, Alfa Wasserman

Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead  
Science, Vertex, Merck, Janssen, AbbVie

---

# Current Situation of Hepatitis C in Italy

---

- 0.8% HCVRNA infected general population
  - > 300,000 HCV carriers in NHS claims registry
  - 10,000 deaths x year
  - > 500 LT per year due to end-stage hepatitis C
  - Total treated with DAA = 109,428 on Jan 1st 2018
  - Total treated in 2017 = 45,201
-

# Current Resources and Programs for HCV in Italy

---

- Eu 2.5 billion between 2014-2017
  - Sof-Vel ,Gle-Pib,Elb-Grz to be reimbursed by NHS
  - Targeted screening (blood donors)
  - Access to treatment: severity criteria lifted & reduced price
-

# Future Actions Planned

---

- Regional plans,i.e. screening of migrants targeting Sicily
  - Regional plans to facilitate access(Veneto,Lombardy,Sicily)
  - Triplet (NS5b,NS5a,PI)
  - Implementation of Viral Hepatitis National Plan including a nationwide registry
-